AVITA Medical is attempting a high-stakes med-tech turnaround, using RECELL GO and a broader wound-care portfolio to convert a discounted burn-treatment niche into a scalable regenerative medicine platform.
Overview
AVITA Medical is a speculative but compelling med-tech turnaround. Under permanent CEO Cary Vance, the company has stabilized operations, refocused sales on high-volume accounts, resolved key reimbursement issues, and refinanced debt with Perceptive Advisors. Revenue is growing, costs are falling, insider buying is notable, and valuation remains depressed at under 2x trailing revenue. The opportunity is asymmetric: RECELL GO, RECELL GO mini, Cohealyx, and PermeaDerm could transform AVITA from a single-product burn company into a broader acute wound-care platform.